The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?
Alexandre GiraudoRenaud SabatierFrederique RousseauAlexandre de NonnevilleAnthony GoncalvesMaud CecileCecile BraticevicFrederic ViretLorene SeguinMaria KfouryDorothée NaudetMarie HamonLouis TassyPublished in: Cancers (2024)
Overall, CDK4/6is present a favorable benefit-risk profile in older BC patients, at least in advanced BC; however, further research is warranted to optimize treatment strategies and improve outcomes in this population.